Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orfadin and Nitinosine Study
NCT04113772Unknown
- Sponsor
- Sutphin Drugs
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nitisinone in hereditary tyrosinemia type 1 (HT1) (2 arms), sponsored by Sutphin Drugs. Primary endpoint: Succinylacetone level at 8 weeks. Status: unknown.
02
Drugs
nitisinone
03
Conditions
hereditary tyrosinemia type 1 (HT1)
Beyond the preview
Go deeper on NCT04113772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113772.